Skip to content

A clinical trial on KUPPAIMENI CHOORANAM in the management of IRAIPPU IRUMAL(BRONCHIAL ASTHMA)

A Prospective Open labelled non randomized phase II clinical study on KUPPAIMENI CHOORANAM in the management of IRAIPPU IRUMAL(BRONCHIAL ASTHMA)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031231
Enrollment
60
Registered
2021-02-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: KUPPAIMENI CHOORANAM: 30mg/Kg/BW/Twice a day(orally) with Hot water Control Intervention1: NIL: NIL

Sponsors

Government Siddha Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient with the symptoms of dry cough, recurrent attacks of dyspnoea,hoarseness of voice,tightness of chest,profuse sweating and wheezing 2.History of allergens, climatic changes 3.Patients who are willing to take radiological investigation and provide blood for lab investigation.

Exclusion criteria

Exclusion criteria: 1.Cardiac Diseases 2.Chronic allergic bronchitis 3.Tuberculosis 4.COPD 5.Pregnancy and Lactating mother 6.Restrictive airway disease 7.Status Asthmaticus 8.Systemic Hypertension 9.Autoimmune Diseases 10.Drugs and Chemicals

Design outcomes

Primary

MeasureTime frame
If during treatment or after treatment reduction of the following symptoms 1.Dry cough 2.Recurrent attacks of dyspnoea 3.Hoarseness of voice 4.Tightness of chest 5.Profuse sweating 6.WheezingTimepoint: 45 days

Secondary

MeasureTime frame
1.To evaluate the pharmacological activities 2.Study about the prevalence of Iraippu Irumal in relation between diet and life styles 3.To determine about Antimicrobial activities in different solvents 4.To find out primary phytochemical analysis in trial drug 5.To evaluate spirometric changes in Iraippu Irumal 6.To evaluate safety profile for acute and subacute toxicity 7.To perform bio chemical analysisTimepoint: 45 days

Countries

India

Contacts

Public ContactProfDr A Manoharan MDsPhD

Government Siddha Medical College and Hospital

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026